Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors

• US 7,871,619 B2
• Filed: 08/04/2004
• Issued: 01/18/2011
• Est. Priority Date: 11/30/2001
• Status: Active Grant

• Current Assignee: ChemoCentryx, Inc. (Amgen Inc.)
• Original Assignee: ChemoCentryx, Inc. (Amgen Inc.)
• Inventors: Summers, Bretton, Burns, Jennifer M., Miao, Zhenhua, Schall, Thomas J., Howard, Maureen C.
• Primary Examiner(s): Bunner; Bridget E
• Assistant Examiner(s): Hamud; Fozia M
• Application Number:
  US10/912,638
• Publication Number:
  US 20050074826A1
• Time in Patent Office: 2,358 Days
• Field of Search: None
• US Class Current: 424/143.1
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons
• CPC Class Codes: G01N 2500/00 Screening for compounds of potential therapeutic value
• CPC Class Codes: G01N 33/5011 for testing antineoplastic activity
• CPC Class Codes: G01N 33/57407 Specifically defined cancers
• CPC Class Codes: G01N 33/57411 of cervix
• CPC Class Codes: G01N 33/57415 of breast
• CPC Class Codes: G01N 33/57426 leukemia
• CPC Class Codes: G01N 33/57434 of prostate
• CPC Class Codes: G01N 33/6863 Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors

Abstract

Ligands of CCX-CKR2 and the biological role of CCX-CKR2 in cancer is described.

Claims

1. A method of treating a cancer in an individual, wherein cancer cells in the individual express CCX-CKR2, the method comprising administering to the individual a therapeutically effective amount of an antibody that binds to the extracellular domain of the amino acid sequence of SEQ ID NO:

2.

2. The method of claim 1, wherein the antibody is identified by a method comprising

contacting a plurality of antibodies to a CCX-CKR2 polypeptide comprising an extracellular domain at least 95% identical to an extracellular domain of the amino acid sequence of SEQ ID NO:

2, or a SDF1 or I-TAC-binding fragment thereof; and

selecting an antibody that competes with I-TAC or SDF-1 for binding to the CCX-CKR2 polypeptide or fragment thereof, thereby identifying an antibody that treats cancer.

3. The method of claim 1, wherein the cancer is not Kaposi'"'"'s sarcoma, multicentric Castleman'"'"'s disease or AIDS-associated primary effusion lymphoma.

4. The method of claim 1, wherein tumor formation is inhibited.

5. The method of claim 1, wherein tumor volume is reduced.

6. The method of claim 1, wherein the cancer comprises a mammary carcinoma.

7. The method of claim 1, wherein the cancer comprises a B cell lymphoma.

8. The method of claim 1, wherein the cancer comprises a lung carcinoma.

9. The method of claim 1, wherein the cancer is selected from the group consisting of mammary carcinoma, glioblastoma, prostate carcinoma, B cell lymphoma, ovarian carcinoma, and lung carcinoma.

10. The method of claim 1, wherein the antibody is identified by a method comprising

contacting a plurality of antibodies to a CCX-CKR2 polypeptide comprising an extracellular domain of the amino acid sequence of SEQ ID NO:

2; and

selecting an antagonistic antibody that competes with I-TAC or SDF-1 for binding to the CCX-CKR2 polypeptide, thereby identifying an antibody that treats cancer.